PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1
Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for
patients with relapsed and refractory acute myeloid leukemia.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University